Abstract
Renal cell carcinoma (RCC) is the sixth leading cause of cancer-related deaths and is responsible for an estimated 95,000 deaths worldwide. Metastatic RCC is refractory to radiation therapy and traditional chemotherapy. Treatment of metastatic RCC with either interleukin 2 (IL-2) or interferon-alfa (IFN-α) has demonstrated a response rate of approximately 15%. Identification of and research into the von Hippel-Lindau (VHL) gene has led to the development of multi-kinase inhibitors and other novel molecular targeting therapies. Sunitinib and sorafenib are now commercially available agents that can improve progression-free survival. Additional targeting agents are currently under clinical investigation. Combination trials of molecular targeting agents and cytokines are ongoing in the metastatic setting as are trials using molecular targeting agents in the adjuvant setting. This review focuses on the recent advances of targeted therapy for RCC.
Similar content being viewed by others
References
Vogelzang NJ, Stadler WM (1998) Kidney cancer. Lancet 352(9141):1691–1696
Jemal A, Siegel R, Ward E et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56(2):106–130
Mathew A, Devesa SS, Fraumeni JF Jr, Chow WH (2002) Global increases in kidney cancer incidence, 1973–1992. Eur J Cancer Prev 11(2):171–178
Linehan WM, Zbar B, Bates SE et al (2001) Cancer of the kidney and ureter, 6th edn. Lippincott, Williams and Wilkins, Philadelphia, PA
Couillard DR, deVere White RW (1993) Surgery of renal cell carcinoma. Urol Clin North Am 20(2):263–275
Flanigan RC, Salmon SE, Blumenstein BA et al (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345(23):1655–1659
Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358(9286):966–970
Negrier S, Perol D, Ravaud A et al (2005) Do cytokines improve survival in patients with metastatic renal cell carcinoma (RCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial. Proc Am Soc Clin Oncol 23:4511
Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13(3):688–696
Yang JC, Sherry RM, Steinberg SM et al (2003) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21(16):3127–3132
McDermott DF, Regan MM, Clark JI et al (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23(1):133–141
Yagoda A, Petrylak D, Thompson S (1993) Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 20(2):303–321
Kaelin WG Jr (2002) Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2(9):673–682
Jacobsen J, Rasmuson T, Grankvist K, Ljungberg B (2000) Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 163(1):343–347
Turner KJ, Moore JW, Jones A et al (2002) Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 62(10):2957–2961
Gordon MS, Margolin K, Talpaz M et al (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19(3):843–850
Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti–vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349(5):427–434
Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL (2004) Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 10(8):2584–2586
Riedel F, Gotte K, Li M, Hormann K, Grandis JR (2002) EGFR antisense treatment of human HNSCC cell lines down-regulates VEGF expression and endothelial cell migration. Int J Oncol 21(1):11–16
Ciardiello F, Caputo R, Bianco R et al (2001) Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7(5):1459–1465
Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A (2005) Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 23(31):7889–7896
Bukowski RM, Kabbinavar F, Figlin RA et al (2006) Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 24:4523
Thompson DS, Greco FA, Spigel DR et al (2006) Bevacizumab, erlotinib, and imatinib in the treatment of patients with advanced renal cell carcinoma: Update of a multicenter phase II trial. Proc Am Soc Clin Oncol 24:4594
Mendel DB, Laird AD, Xin X et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9(1):327–337
Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2(5):471–478
Faivre S, Delbaldo C, Vera K et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24(1):25–35
Motzer RJ, Michaelson MD, Redman BG et al (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24(1):16–24
Motzer RJ, Rini BI, Bukowski RM et al (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295(21):2516–2524
Motzer RJ, Hutson TE, Tomczak P et al (2006) Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alpha (INF-a) as first-line systemic therapy for patients with metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 24:LBA3
Ronnen EA, Kondagunta GV, Lau C et al (2006) A phase I study of sunitinib malate (SU11248) in combination with gefitinib in patients with metastatic renal cell carcinoma (mRCC). Proc Am Soc Clin Oncol 24:4537
De Mulder PH, Roigas S, Gillessen S et al (2006) A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 24(18):223S
Sunitinib malate alone and in combination with interferon alfa as first-line therapy for metastatic renal cell cancer http://www.clinicaltrials.gov/ct/show/NCT00267748?order=4
Rini BI, George DJ, Michaelson MD et al (2006) Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastic renal cell carcinoma (mRCC). Proc Am Soc Clin Oncol 24:4522
Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64(19):7099–7109
Awada A, Hendlisz A, Gil T et al (2005) Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 92(10):1855–1861
Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ (2005) Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 11(15):5472–5480
Moore M, Hirte HW, Siu L et al (2005) Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 16(10):1688–1694
Strumberg D, Richly H, Hilger RA et al (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23(5):965–972
Ratain MJ, Eisen T, Stadler WM et al (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24(16):2505–2512
Escudier B, Szczylik C, Eisen T et al (2005) Randomized phase III trial of the raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 23:4510
Escudier B, Szczylik C, Eisen T et al (2005) Randomized phase III trial of the multi-kinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Eur J Cancer Suppl 3(2):226
Eisen T, Bukowski RM, Staehler M et al (2006) Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival. Proc Am Soc Clin Oncol 24:4524
Escudier B, Szczylik C, Demkow T et al (2006) Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (INF) in treatment-naive patients with metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 24:4501
Ryan CW, Goldman BH, Lara PN et al (2006) Sorafenib plus interferon-a2b (INF) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412. Proc Am Soc Clin Oncol 24:4525
Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20(1):289–296
Gollob J, Richmond T, Jones J et al (2006) Phase II trial of sorafenib plus interferon-alpha 2b (INF-α2b) as first-or second-line therapy in patients with metastatic renal cell cancer. Proc Am Soc Clin Oncol 24:4538
Atkins MB, Hidalgo M, Stadler WM et al (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22(5):909–918
Hudes G, Carducci M, Tomczak P et al (2006) A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR+ IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). Proc Am Soc Clin Oncol 24:LBA4
Motzer RJ, Bacik J, Schwartz LH et al (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22(3):454–463
Mekhail TM, Abou-Jawede RM, Boumerh G et al (2005) Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23(4):832–841
Amato RJ, Misellati A, Khan M et al (2006) A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). Proc Am Soc Clin Oncol 24:4530
Zafar Y, Bendell J, Lager J et al (2006) Prelimary results of a phase I study of bevacizumab (BV) in combination with everolimus (E) in patients with advanced solid tumors. Proc Am Soc Clin Oncol 24:3097
Rugo HS, Herbst RS, Liu G et al (2005) Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 23(24):5474–5483
Rini BI, Rixe O, Bukowski RM et al (2005) AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). Proc Am Soc Clin Oncol 23:4509
Phase 2 study of AG-013736 in patients with refractory metastatic renal cell cancer. http://www.clinicaltrials.gov/ct/show/NCT00282048?order=1
Keryx Biopharmaceuticals, Inc. announced positive date of KRX-0401 (perifosine) in patients with advanced renal cell carcinoma (RCC). Kidney Cancer News XVI (6). http://app.e2ma.net/app/view:CampaignPublic/id:160.313886690/rid:7471aff0ead7ca63a77f1c3498cd6dd6
Wedge SR, Kendrew J, Hennequin LF et al (2005) AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65(10):4389–4400
Drevs J, Medinger M, Mross K et al (2005) Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors. Proc Am Soc Clin Oncol 23:3002
AZD2171 in treating patients with refractory kidney cancer. http://www.clinicaltrials.gov/ct/show/NCT00303862?order=11
Suttle B, Hurwitz H, Dowlati A et al (2005) Pharmacokinetics (PK) and tolerability of GW786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumors. Proc Am Soc Clin Oncol 22:3054
Hurwitz H, Dowlati A, Savage S et al (2005) Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors. Proc Am Soc Clin Oncol 24:3012
GW786034 in subjects with locally recurrent or metastatic clear cell renal cell carcinoma. http://www.clinicaltrials.gov/ct/show/NCT00244764?order=1
GW786034 (pazopanib) in metastatic renal cell carcinoma. http://www.clinicaltrials.gov/ct/show/NCT00334282?order=1
George D, Michaelson M, Oh W et al (2003) Phase I study of PTK787/ZK222584 (PTK/ZK) in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 22:1548
Vatalanib and everolimus in treating patients with advanced solid tumors. http://www.clinicaltrials.gov/ct/show/NCT00303732?order=12
Eder J, Appleman L, Heath E et al (2006) A phase I study of a novel spectrum selective kinase inhibitor (SSKI), XL880, administered orally in patients (pts) with advanced solid tumors (STs). Proc Am Soc Clin Oncol 24:3041
Phase 2 study of XL880 in subjects with papillary renal cell carcinoma. http://www.clinicaltrials.gov/ct/show/NCT00345423?order=3
Sunitinib or sorafenib in treating patients with kidney cancer that was removed by surgery http://www.clinicaltrials.gov/ct/show/NCT00326898?order=1
A phase III randomised controlled study comparing sorafenib with placebo in patients with resected primary renal cell carcinoma at high or intermediate risk of relapse. http://www.ctu.mrc.ac.uk/studies/RE05.asp
Veronese ML, Mosenkis A, Flaherty KT et al (2006) Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 24(9):1363–1369
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Villanueva, M.L.H., Hauke, R. Targeted therapies for renal cell carcinoma. Targ Oncol 2, 7–16 (2007). https://doi.org/10.1007/s11523-006-0041-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11523-006-0041-2